BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24290215)

  • 1. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
    Ahn IE; Natelson E; Rice L
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S300-4. PubMed ID: 24290215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
    Christoforidou A; Pantelidou D; Anastasiadis A; Goutzouvelidis A; Margaritis D; Kotsianidis I; Spanoudakis E; Kaloutsi V; Bourikas G; Tsatalas C
    Acta Haematol; 2008; 120(4):195-8. PubMed ID: 19129692
    [No Abstract]   [Full Text] [Related]  

  • 4. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 6. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
    Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
    Antelo ML; de Las Heras N; Gonzalez Porras JR; Kerguelen A; Raya JM
    Expert Rev Hematol; 2015 Dec; 8(6):819-35. PubMed ID: 26368319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
    Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
    Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
    Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
    Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G
    Leukemia; 2019 Aug; 33(8):1996-2005. PubMed ID: 31142846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
    Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.